By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Stem cell technology company Cellular Dynamics International and Madison, Wisconsin-based life sciences company Promega today announced plans to collaborate on validating predictive drug discovery toxicity tests that rely on CDI's induced pluripotent stem cells and cytotoxicity and cell viability assays from Promega.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.